M104 peptide
M104 peptide is an OXA-48 carbapenemase inhibitor and antibiotic potentiator. M104 peptide effectively blocks the binding and active site cavity of OXA-48. M104 peptide restores Meropenem (HY-13678)’s antibacterial activity against OXA-48-producing Klebsiella pneumoniae. M104 peptide can be used for the research of Carbapenem-resistant Klebsiella pneumoniae infection.
For research use only. We do not sell to patients.
- Formula: C117H173N29O29S
- Molecular Weight:2481.87
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Beta-lactamase Isoforms
More
Biological Activity
M104 peptide (7-125 μg/mL; 18 h) reduces the meropenem MIC by 4-fold against a meropenem-resistant, blaOXA-48-harboring Klebsiella pneumoniae strain, restoring intermediate susceptibility to meropenem[1].
Peptide M104 (50-200 μg/mL; 18 h) enhances meropenem's biofilm inhibition activity against strong biofilm-forming blaOXA-48-positive Klebsiella pneumoniae clinical isolates, reducing meropenem MBIC values by two-fold for all 5 tested isolates, though the overall effect is not statistically significant (p-value = 0.06)[2].
Peptide M104 (200 μg/mL; 24-48 h) is non-cytotoxic to HDFa cells after 24 h of incubation, but causes a significant 9.9% reduction in cell viability after 48 h of incubation[2].
Peptide M104 (200 μg/mL; 1 h) exhibits no hemolytic activity against fresh human red blood cells after 1 h of incubation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human dermal fibroblast (HDFa) cell line
-
Concentration:200 μg/mL
-
Incubation Time:24 h; 48 h
-
Result:Maintained a mean cell viability of 99.6% in HDFa cells after 24 h of incubation, which was not statistically different from the untreated control (p-value > 0.05).
Reduced mean cell viability significantly to 90.1% after 48 h of incubation compared to the untreated control (p-value < 0.05).
Chemical Information
-
Molecular Weight 2481.87
-
Formula C117H173N29O29S
-
Sequence
Met-Glu-Ala-Phe-Ile-Val-Ser-Ala-Phe-Lys-His-Gln-Ala-Glu-Gly-Phe-Lys-Leu-His-Tyr-Lys
-
Sequence Shortening
MEAFIVSAFKHQAEGFKLHYK
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Sadeghi S, et al. Design of novel human microbiome-derived peptides for inhibition of OXA-48 Carbapenemase: An in-silico and in-vitro approach. Microb Pathog. 2025;206:107779. [Content Brief]
[2]. Sadeghi S, et al. Enhanced meropenem activity by a microbiome derived peptide targeting oxacillinase 48 carbapenemase in carbapenem resistant Klebsiella pneumoniae isolates. Sci Rep. 2026;16(1):7589. Published 2026 Feb 6. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
- M104 peptide
- Beta-lactamase
- Bacterial
- meropenem
- OXA-48 carbapenemase
- carbapenem-resistant klebsiella pneumoniae infection
- HDFa cell
- carbapenem-resistant Klebsiella pneumoniae clinical isolates
- blaOXA-48-harboring Klebsiella pneumoniae strain
- Klebsiella pneumoniae
- biofilm
- fresh human red blood cells
- OXA-48-like carbapenemase
- Inhibitor
- inhibitor
- inhibit